FDA rejects Pozen's Yosprala, again; shares plummet
This article was originally published in Scrip
Executive Summary
Shares of Pozen plummeted 26.7%, or a loss of $2.41, in premarket trading on 17 December after the company revealed the FDA had again rejected the company's new drug application (NDA) to market Yosprala (PA8140/ PA32540), the firm's its combination immediate-release generic omeprazole and enteric-coated (EC) delayed-release aspirin tablets.